Module 107

Jump to: Home | General properties | Gene sets | Enriched clinical annotations | Enriched Go annotations | Visual display
General Properties
Below we list the number of gene sets from which the module was composed was originally composed, and the number of genes and experiments that it contains. Clicking on the number of genes will display a detailed list of all the genes in the module. Clicking on the number of experiments will display a detailed list of all the experiments in the module.
Num gene sets: 2
Num genes: 80 (see 2045 additional genes for this module)
Num experiments: 618 (242 induced, 376 repressed)
Parent module: 172
Children modules: None


Jump to: Home | General properties | Gene sets | Enriched clinical annotations | Enriched Go annotations | Visual display
Gene sets
Below we list the gene sets from which the module was originally composed. Clicking on a gene set will display all the genes associated with that gene set. Also listed are all the other modules in which the gene set participates.
regulation of catabolism
proteolysis and peptidolysis


Jump to: Home | General properties | Gene sets | Enriched clinical annotations | Enriched Go annotations | Visual display
Enriched clinical annotations
For each of the clinical annotations, we tested whether it was enriched in the set of arrays in which the module is significantly induced (or repressed). Below we list all such annotations that were enriched in this module with an FDR corrected p-value of 0.05 ('P-value' column), along with the number ('Hits' column) of induced (or repressed) module's arrays in which they appear. We also show the fraction of the module's induced (or repressed) arrays with the given annotation ('Hits (%)' column). For completeness, we also list the total number of relevant induced arrays in the module ('Module hits in category' column), total number of arrays in the compendium in which the corresponding annotation is present ('Arrays in annotation' column), and the total number of relevant arrays in the compendium ('Arrays' column). Note that the 'relevant' arrays may be different for each annotation, since it includes only arrays in which the annotation was relevant (i.e., present or not present) and excludes arrays where the value of the annotation was not known. Rows that correspond to annotations that were enriched in the induced arrays of the module have a red background, while rows corresponding to annotations enriched in the repressed arrays have a green background. For each annotation, we also list the other modules in which it was enriched.
Clinical annotation Category P-value Hits Hits(%) Module hits in category Arrays in annotation Arrays
Cancer and cell line (Lung cancer*) Lung cancer* 1.6e-38 133 35.3 376 252 1945
Cancer (Lung cancer*) Lung cancer* 1.6e-38 133 35.3 376 252 1945
Lung tissue, cancer or cell line (Lung cancer*) Lung cancer* 1.3e-36 138 36.7 376 276 1945
Lung cancer (Lung cancer*) Lung cancer* 5.8e-34 123 32.7 376 238 1945
Lung cancer or cell line (Lung cancer*) Lung cancer* 5.8e-34 123 32.7 376 238 1945
Liver tissue (Liver cancer*) Liver cancer* 9.9e-25 75 30.9 242 187 1945
Liver tissue, cancer or cell line (Liver cancer*) Liver cancer* 5.1e-23 75 30.9 242 197 1945
Non small cell lung cancer and cell line (Lung cancer*) Lung cancer* 5.5e-21 95 25.2 376 205 1945
Non small cell lung cancer (Lung cancer*) Lung cancer* 5.5e-21 95 25.2 376 205 1945
Non-tumor liver tissue (Liver cancer) Liver cancer 1.9e-15 54 72 75 76 207
Cancer and cell line (Liver cancer) Liver cancer 1.2e-13 50 100 50 126 207
Hepatitis infected liver (Liver cancer*) Liver cancer* 6.4e-13 52 21.4 242 156 1945
B cells (Leukemia) Leukemia 2.1e-12 34 91.8 37 62 141
Diffuse large B cell lymphoma - DLBCL (B lymphoma) B lymphoma 5.1e-11 39 95.1 41 126 245
Diffuse large B cell lymphoma tumor or cell line (B lymphoma) B lymphoma 7.7e-10 39 95.1 41 134 245
Primary blood mononuclear cells (Leukemia) Leukemia 1.3e-08 17 45.9 37 21 141
Cell line (Breast cancer) Breast cancer 3.8e-08 19 55.8 34 30 152
Bone marrow (Leukemia) Leukemia 1.6e-07 17 45.9 37 23 141
Normal tissue (Liver cancer) Liver cancer 2.8e-07 14 18.6 75 14 207
Liver cancer cell line (Liver cancer) Liver cancer 3.2e-07 10 20 50 10 207
Acute lymphocytic leukemia (Leukemia) Leukemia 4.8e-07 40 95.2 42 99 149
Breast cancer cell line (Breast cancer) Breast cancer 5.4e-07 13 38.2 34 17 152
Activated B like DLBCL (B lymphoma) B lymphoma 6.4e-07 16 39.0 41 30 245
Lymphocytes (Leukemia) Leukemia 1.7e-06 35 94.5 37 91 141
Cell line (Liver cancer) Liver cancer 2.8e-06 10 20 50 11 207
Lymphoma or lymphoma cell line (B lymphoma) B lymphoma 8.0e-06 39 95.1 41 167 245
Female hormonal cancer cell line (Breast cancer) Breast cancer 1.1e-05 11 32.3 34 15 152
Metastasis (Liver cancer) Liver cancer 1.2e-05 9 18 50 10 207
Adenocarcinoma (Breast cancer*) Breast cancer* 1.6e-05 30 12.3 242 112 1945
Breast cancer (Breast cancer*) Breast cancer* 1.6e-05 30 12.3 242 112 1945
Cancer (Breast cancer*) Breast cancer* 1.6e-05 30 12.3 242 112 1945
Female hormonal cancer (Breast cancer*) Breast cancer* 1.6e-05 30 12.3 242 112 1945
Centroblasts (Various tumors) Various tumors 1.7e-05 5 26.3 19 5 154
GC B like DLBCL (Various tumors) Various tumors 1.7e-05 5 26.3 19 5 154
Breast tissue or cancer (Breast cancer*) Breast cancer* 1.8e-05 31 12.8 242 118 1945
Female hormonal tissue or cancer (Breast cancer*) Breast cancer* 1.8e-05 31 12.8 242 118 1945
Cancer (Liver cancer) Liver cancer 4.0e-05 40 80 50 115 207
B. petrussis 537 stimulated immune cells (Stimulated PBMC) Stimulated PBMC 5.4e-05 5 22.7 22 5 144
Stage T1 (Lung cancer) Lung cancer 6.0e-05 93 89.4 104 153 195
Lung carcinoid (Lung cancer) Lung cancer 0.0001 18 13.0 138 20 276
Female hormonal cancer or cell line (Breast cancer*) Breast cancer* 0.0002 30 12.3 242 127 1945
Breast cancer or cell line (Breast cancer*) Breast cancer* 0.0002 30 12.3 242 128 1945
After doxorubicin chemotherapy (Breast cancer) Breast cancer 0.0002 15 88.2 17 21 38
GC B like DLBCL (B lymphoma) B lymphoma 0.0003 18 43.9 41 53 245


Jump to: Home | General properties | Gene sets | Enriched clinical annotations | Enriched Go annotations | Visual display
Enriched GO annotations
For each GO annotation, we tested whether it was enriched in the set of genes of the module. Below we list all such annotations that were enriched in this module with an FDR corrected p-value of 0.05 ('P-value' column), along with the number ('Hits' column) of the module's genes in which they appear. We also show the fraction of the module's genes with the given GO annotation that are included in this module ('Hits (%)' column). For completeness, we also list the total number of genes in the module ('Module genes' column), total number of genes in the compendium in which the corresponding annotation is present ('Genes in annotation' column), and the total number of genes in the compendium ('Genes' column).
GO annotation P-value Hits Hits(%) Module genes Genes in annotation Genes
proteolysis and peptidolysis 6.9e-123 80 100 80 176 4566
peptidase activity 3.4e-106 76 95 80 193 4566
regulation of catabolism 1.5e-97 70 87.5 80 162 4566
catabolism 7.9e-87 70 87.5 80 215 4566
regulation of metabolism 1.8e-68 70 87.5 80 365 4566
hydrolase activity 2.2e-54 76 95 80 783 4566
endopeptidase activity 3.8e-54 43 53.7 80 99 4566
serine-type endopeptidase activity 1.9e-42 33 41.2 80 69 4566
trypsin activity 2.0e-40 29 36.2 80 50 4566
serine-type peptidase activity 1.0e-39 33 41.2 80 80 4566
chymotrypsin activity 4.4e-39 28 35 80 48 4566
metallopeptidase activity 5.7e-33 28 35 80 70 4566
catalytic activity 8.0e-29 76 95 80 1677 4566
metalloexopeptidase activity 9.7e-19 13 16.2 80 21 4566
exopeptidase activity 9.2e-17 12 15 80 21 4566
metalloendopeptidase activity 1.2e-14 14 17.5 80 46 4566
collagen catabolism 6.6e-14 9 11.2 80 13 4566
zinc ion binding 1.3e-13 18 22.5 80 108 4566
protein catabolism 1.4e-12 10 12.5 80 23 4566
cysteine-type peptidase activity 2.2e-12 11 13.7 80 32 4566
macromolecule catabolism 4.0e-12 10 12.5 80 25 4566
transition metal ion binding 1.4e-11 19 23.7 80 160 4566
sterol regulatory element-binding protease activity 2.4e-11 9 11.2 80 21 4566
metal ion binding 7.2e-11 28 35 80 410 4566
cysteine-type endopeptidase activity 1.0e-10 9 11.2 80 24 4566
carboxypeptidase activity 6.1e-10 7 8.7 80 13 4566
metallocarboxypeptidase activity 1.0e-08 6 7.5 80 11 4566
aminopeptidase activity 2.9e-08 5 6.2 80 7 4566
extracellular space 8.6e-08 17 21.2 80 212 4566
blood coagulation factor activity 3.4e-07 5 6.2 80 10 4566
carboxypeptidase A activity 3.4e-07 5 6.2 80 10 4566
aspartic-type endopeptidase activity 4.3e-07 4 5 80 5 4566
blood coagulation 1.3e-06 8 10 80 48 4566
hemostasis 1.8e-06 8 10 80 50 4566
defense/immunity protein activity 9.7e-06 10 12.5 80 103 4566
complement activity 1.0e-05 5 6.2 80 18 4566
lysosome 5.0e-05 7 8.7 80 57 4566
regulation of complement activation 5.8e-05 5 6.2 80 25 4566
complement activation 7.1e-05 5 6.2 80 26 4566


Jump to: Home | General properties | Gene sets | Enriched clinical annotations | Enriched Go annotations | Visual display
Visual display
Below is a visual display of the module. Shown are those arrays in which the module's genes significantly change, and the direction of change (induction/repression) in each array is indicated (middle, labeled 'Module changes'; red/green row). The arrays that correspond to the significant clinical attributes are also shown (top; brown rows). The gene sets that compose the module are also shown (left) along with an indication of the membership of the module genes in these gene sets.
You can also view the images within GeneXPress by loading the module gxp file file.
Note: Since there are 618 experiments, this image does not display the individual experiment names, but rather condenses each experiment to a single pixel without displaying its name. You can fully view the image for this module within GeneXPress, by loading any of the four files mentioned in the line above
 
 





 >4x